Cartesian Therapeutics   Report issue

For profit Phase 1 Phase 2 Phase 3
Founded: Rockville MD United States (2016)

Organization Overview

First Clinical Trial
2018
NCT03448978
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2023

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

Cartesian Therapeutics

Active Ingredients

Drugs in Phase 3 Trials (1)

Key: Cartesian Therapeutics (0) Acquired (1)

rapamycin (5 trials)

Drugs in Phase 2 Trials (9)

Key: Cartesian Therapeutics (4) Acquired (5)

bcma-pd1-cart cell (4 trials)

candida urate oxidase (1 trial)

descartes 11 (1 trial)

descartes-25 (1 trial)

descartes 30 (1 trial)

pegloticase (krystexxa) (1 trial)

pegsiticase (3 trials)

sel-302 (1 trial)

sirolimus (rapamune) (2 trials)

Drugs in Phase 1 Trials (6)

Key: Cartesian Therapeutics (3) Acquired (3)

cyclophosphamide (cytoxan) (2 trials)

descartes-11 (1 trial)

fludarabine (fludara) (2 trials)

sel-068 (1 trial)

sela-070 (1 trial)

sodium chloride (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Acute Lung Injury (Phase 2)

Multiple Myeloma (Phase 2)

Muscle Weakness (Phase 2)

Myasthenia Gravis (Phase 2)

Neoplasms, Plasma Cell (Phase 2)

Respiratory Distress Syndrome (Phase 2)

Respiratory Distress Syndrome, Newborn (Phase 2)

Syndrome (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 17
  • # of Trial APIs: 16